{"organizations": [], "uuid": "c28f5a1b9a1c8c8929c11be21ce20c93a16a735a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-matinas-biopharma-achieves-statist/brief-matinas-biopharma-achieves-statistical-endpoint-for-success-inphase-2a-clinical-study-of-orally-administered-mat2203-idUSFWN1P30IX", "country": "US", "domain_rank": 408, "title": "BRIEF-Matinas BioPharma Achieves Statistical Endpoint For Success In Phase 2a Clinical Study Of Orally-Administered MAT2203", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.794, "site_type": "news", "published": "2018-01-08T20:11:00.000+02:00", "replies_count": 0, "uuid": "c28f5a1b9a1c8c8929c11be21ce20c93a16a735a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-matinas-biopharma-achieves-statist/brief-matinas-biopharma-achieves-statistical-endpoint-for-success-inphase-2a-clinical-study-of-orally-administered-mat2203-idUSFWN1P30IX", "ord_in_thread": 0, "title": "BRIEF-Matinas BioPharma Achieves Statistical Endpoint For Success In Phase 2a Clinical Study Of Orally-Administered MAT2203", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "matinas biopharma holdings inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Matinas Biopharma Holdings Inc:\n* MATINAS BIOPHARMA ACHIEVES STATISTICAL ENDPOINT FOR SUCCESS IN PHASE 2A CLINICAL STUDY OF ORALLY-ADMINISTERED MAT2203 FOR THE TREATMENT OF CHRONIC REFRACTORY MUCOCUTANEOUS CANDIDIASIS\n* MATINAS BIOPHARMA - ‍INVESTIGATORS FROM NATIONAL INSTITUTES OF HEALTH RELAYED POSITIVE DATA FROM THIRD PATIENT ENROLLED IN PHASE 2A STUDY OF MAT2203​\n* MATINAS BIOPHARMA HOLDINGS INC - THE THIRD PATIENT MET PRIMARY ENDPOINT OF PHASE 2A STUDY WITH TREATMENT OF MAT2203​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T20:11:00.000+02:00", "crawled": "2018-01-09T17:11:41.015+02:00", "highlightTitle": ""}